Trends Immunol. 2025 Jul 11:S1471-4906(25)00169-3. doi: 10.1016/j.it.2025.07.002. Online ahead of print.
ABSTRACT
Pharmacological activation of the stimulator of interferon genes (STING) pathway triggers inflammatory innate immune responses to potentially reinvigorate tumor immunogenicity. Recent work by Dang et al. revealed an alternative paradigm: a clinically approved old drug was repurposed to boost STING signaling and immune activation via a mode of action distinct from that of conventional STING agonists.
PMID:40651881 | DOI:10.1016/j.it.2025.07.002